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Review Article
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Aga Khan University, Karachi.
Abstract
Pregnancy and puerperium are most prevalent pro-
thrombotic states leading to cerebral venous thrombosis.
Likelihood of stroke to be of venous origin is greater in
stroke associated with pregnancy compared to stroke unre-
lated to pregnancy. Pregnancy induces several changes in
coagulation system, which persists at least during early
puerperium, rendering it a prothrombotic state.
Hypercoaguability worsens further after delivery as a result
of volume depletion and trauma. During puerperium addi-
tional risk factors include infection and instrumental deliv-
ery or Caesarean section. The management follows general
rules as for the venous thrombosis unrelated to pregnancy,
however the prognosis is different. 
Introduction
Pregnancy and puerperium are well established
causes of venous thromboembolism (VTE), including
intracranial venous thrombosis.1,2 Several physiological
changes in coagulation system render pregnancy and puer-
perium prothrombotic states.3-8 Since every woman of
reproductive age has potential to become pregnant and
hence is at risk of cerebral venous thrombosis (CVT). The
association was first described by Abercrombie in 1828 and
latter by Collier.9,10 It is important to discuss the association
since no factor is as prevalent as pregnancy. However, not
every pregnant woman develops CVT and it (along with
puerperium) accounts for only 20% of cases.11,12 Further
more the entity may be more common in developing
world.13,14 We will discuss physiology of coagulation sys-
tem during pregnancy, epidemiology of obstetric CVT
(CVT during pregnancy and puerperium), its pathophysiol-
ogy, clinical features, management and prognosis. 
Coagulation during pregnancy and puerperium
Changes in coagulation system i.e. enhancement of
procoagulants and inhibition of anticoagulants, during preg-
nancy are considered to be physiological adaptations of the
body in order to face the haemostatic challenge of delivery.
Significant changes include reduction in protein S levels,
rise in activated protein C (APC) resistance, increments in
fibrinogen, plasminogen activator inhibitors (PAI), pro-
thrombin fragments 1 and 2 (F 1+2), and coagulant activity
of factors V and VIII. 
Protein S (total and free) begins to fall around 10
weeks of gestation and continue to fall through out pregnan-
cy.3,4,7 The protein S activity falls by approximately 50%
compared to normal controls.3,4 Resistance to APC increas-
es through out pregnancy and at term seen in more than half
of normal pregnant women compared to normal non preg-
nant controls.3,5 Interestingly no reduction occurs in
absolute levels of protein C, rather it increases during early
postpartum period.3,7 Similarly no change occurs in
antithrombin (AT) levels.3 Resistance to APC has been
attributed to rise in factors V and VIII.3 The Factor V activ-
ity increases after 16 weeks of gestation and the activity
increases by 29% at term.3 Fibrinogen levels start to rise as
early as 6-7 weeks and continue to rise thereafter.4 From
20th week onwards prothrombin time shortens, probably as
a result of increased levels of factor VII.4 Changes in pro-
tein S, resistance to APC, factors V and VIII, and fibrino-
gen persist during puerperium, at least a few days.3-6 The
levels of F1+2 rise through out pregnancy and fall during
puerperium.3 Fibrinolytic system is inhibited by elevation
of PAI-1 during 3rd trimester.4
Platelets play a very important role in coagulation.
Their concentration remains same during pregnancy.
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However their aggregating ability increases. In addi-
tion their responsiveness to prostacyclin and cAMP forma-
tion is reduced. Over all these changes favor coagulation.8
Epidemiology of obstetric CVT
Pregnancy and puerperium are important risk factors
for CVT and European researchers have reported that it
accounts for about 20% of all CVT cases.11,12 However, lit-
erature from developing countries revealed a higher propor-
tion of obstetric CVT. In his series of 113 patients, Cantu C
et al from Mexico reported that obstetric CVT accounted for
59% of the cases.9 The estimated annual incidence of CVT
(overall) is 3-4 cases per million population and 75% adult
patients are women.11,15 Using National hospital discharge
survey data from US (1979-1991), Lanska DJ et al estimat-
ed risk of peripartum CVT about 8.9/100,000 deliveries.16
The risk is even higher i.e. 11.4/100,000 deliveries for entire
period of pregnancy.17 Recently data from healthcare cost
and utilization project (1993-1994) revealed a risk of
11.6/100,000 deliveries for peripartum intracranial venous
thrombosis.18 The entity is more common in developing
countries. Bansal et al, from India, reported prevalence of
4.5/1000 obstetric cases during early 80s.14 In their autopsy
series, Banerjee K et al during late 80s, found that CVT
accounts for approximately 10% of all strokes.19 Recently
Panagariya et al from India reported that CVT accounts for
half of all young strokes and 40% of strokes in women.20
Despite the fact that pregnancy and puerperium
increase risk of both venous and arterial stroke the propor-
tion of venous stroke is much higher in pregnancy related
stroke as compared to stroke unrelated to pregnancy.2 Jiann-
Shing et al from Taiwan reported that in women of 15-40
years of age, with first ever stroke- proportion of CVT is
39% in pregnancy related stroke as compared to only 5% in
pregnancy unrelated stroke.2
CVT usually presents either late in pregnancy or
puerperium but cases have been reported as early as 8
weeks.21 Majority of studies have reported a higher propor-
tion of CVT during puerperium compared to pregnancy.
However, US literature reported more or less similar pro-
portion.16-18 The ratio of CVT during puerperium and preg-
nancy is reported to be 2.1:1 to 3.25:1 from European coun-
tries and 13:1 to 14:1 from developing countries like
Mexico and India.9,11,12,20 Higher risk during puerperium
has been attributed to bad obstetrical practices i.e. home
deliveries by untrained dais and restriction of water early
after delivery.20
Pathogenesis and Risk Factors of obstetric CVT
Hypercoaguability plays an important role in devel-
opment of CVT during pregnancy and puerperium. As men-
tioned earlier several changes occur in coagulation system,
which are more marked during the third trimester, and ren-
der it a hypercoaguable state. In addition dehydration as a
result blood loss during delivery and bad obstetric practices
and local trauma during delivery worsen the prothrombotic
state. The hypercoaguability and venous stasis as a result of
prolonged bed rest, instrumental delivery or Caesarean sec-
tion will lead to thrombosis.12 Occlusion of cerebral veins
lead to cytotoxic and vasogenic edema, and infarction while
occlusion of major sinuses leads to intracranial hyperten-
sion.15
In addition to these pathophysiologic processes and
factors, several other risk factors have also been noted by
various investigators. 
Cantu et al noted significantly higher proportion of
anaemia and ESR in puerperal cases compared to non puer-
peral cases.9 A significant association has constantly been
found with young age from developing as well as developed
countries.14,16-18 Lanska et al reported that younger group
14-25 years is more vulnerable.16,17 In a series of 138 cases
from India, 112 were under 30 years of age.14 Caesarean
section and infections have been found to be independent
risk factors of obstetric CVT and they increase the risk by
three times.18 Caesarean section may increase the risk by
postsurgical decline of protein C levels, presumably
because surgically induced tissue damage induces the acti-
vation of blood clotting with increased thrombin generation,
which in turn both activates protein C and accelerates its
clearance from plasma.22 Pregnancy induced hypertension
and excessive vomiting have also been reported to con-
tribute independently in development of obstetric CVT.17
Multiparity has been over represented in obstetric CVT,
from developing countries.9,13,14,20 Bansal et al reported a
statistically significant rise in serum triglycerides, phospho-
lipids, free fatty acids, blood platelet count, platelet adhe-
sive index, and fall in blood fibrinolytic activity as com-
pared to normal controls.20
Several isolated cases of pregnancy associated CVT
have been reported in whom other risk factors were docu-
mented so it is wise to remember other risk factors e.g.
homocysteinemia, hypercoaguable states (protein C defi-
ciency, factor V Leiden, mutations in prothrombin gene
20201), vasculitic and other inflammatory processes, trau-
ma and drugs.23-25
Clinical features
Major clinical features of obstetric CVT are similar
to CVT unrelated to pregnancy. These include headache,
focal deficits, seizures and mental status changes. However,
certain important differences have been noted by Cantu et
al.9 They found more acute course and early stabilization.
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They also noted lesser frequency of motor findings and gen-
eralized seizures, and higher frequency of focal seizures at
presentation. However, during the course of disease the dif-
ferences in frequency of seizure type and motor deficits
vanish.9 Mental status changes especially somnolence/
drowsiness were more common in obstetric CVT.9 On the
contrary isolated intracranial hypertension was more fre-
quent in CVT unrelated to pregnancy.9
Differential Diagnosis
It is important to differentiate this condition from
other pregnancy associated central nervous system (CNS)
disorders i.e eclampsia and postpartum cerebral angiopathy.
It is also important to exclude arterial strokes, parenchymal
haemorrhages unrelated to CVT, subarachnoid haemorrhage
(SAH) and CNS infections.
Diagnosis
Most important diagnostic test is MRI and MRV of
brain. LP may be needed to exclude CNS infection. Work
up for hypercoaguability, especially genetic disorders-,
inflammatory and vasculitic disorders is required in select-
ed cases. 
Management
Management of obstetric CVT is not different from
that of CVT unrelated to pregnancy. Hence it includes sup-
portive care, seizure control, measures to lower intracranial
pressure, search and treatment of possible infection. To pre-
vent further thrombosis, anticoagulation is the preferred
treatment, currently. This is based on a few small random-
ized trials and extensive anecdotal experience.26,27 Local
thrombolysis has also been tried in conjunction with sys-
temic intravenous heparin, with encouraging results.28,29
Except Indians none have reported on anticoagulation
specifically in obstetric CVT. Srinivasan  used heparin in
uncontrolled fashion in 80s and noted that mortality was
lower amongst heparin group.13 Recently Nagaraja et al
conducted two randomized controlled trials of low dose
(2500 units thrice daily) unfractionated subcutaneous
heparin in contrast to high dose heparin infusion or low
molecular weight heparin, used in earlier trials in patients
with obstetric CVT and found it beneficial.30,31 The first
trial published in 1995 and heparin was used only in patients
with CVT with out any haemorrhage.29 Second trial pub-
lished in Neurology India in 1999 includes all patients with
puerperal CVT irrespective of the haemorrhage.30 This trial
includes 73 patients in heparin group (27 with haemorrhag-
ic stroke) and 77 in control group (27 with haemorrhagic
stroke). Complete recovery was seen in 34 (47%) patients in
treatment arm as compared to 14 (18%) in control group and
mortality was 8 (11%) vs. 18 (23%). This is an important
and encouraging therapeutic trial. However it is limited by
its design as it was not a placebo controlled double blind
trial and by the fact that higher proportion of patients in con-
trol arm had status epilepticus which might have con-
tributed to higher mortality in control arm.      
Prognosis
Prognosis of CVT is quite variable and the outcome
ranges from total recovery to death. The disease had a fatal
outcome during preimaging era, when neither early diagno-
sis was feasible/possible nor effective therapies and sup-
portive care was available. 
Various obstetric CVT series have reported a mortal-
ity rate from 4-33% (Table 1).9,11,13,20,31-33
Cantu et al reported lower mortality i.e. 9.7 vs.
32.6% in Obstetric CVT. However proportion of complete
recovery was similar in both the groups. 
Favourable outcome has been reported from 60-76%
of cases.9,33 Favorable outcome in obstetric CVT has been
attributed to the assumption that the occlusion is limited and
transient with rapid recanalization or by development of
collaterals.9
Neuropsychiatric manifestations and pseudotumor
cerebri like presentations carry favourable prognosis while
acute fulminant course, bilateral haemorrhagic infarctions
and diffuse cerebral oedema are associated with relatively
poor outcome.20
There is no data on long term outcome including
recurrence during subsequent pregnancy in patients with
obstetric CVT. However, Mehraein et al reported that there
is no substantial risk of CVT during subsequent pregnancy in
women who had CVT in past whether obstetric or not.34 In
their retrospective review 14/39 women had 22 pregnancies
and none developed CVT over a mean follow up of 10 years.
These 14 women also included 4 women in whom index
Table 1. Mortality of CVT associated with pregnancy and puerperi-
um^*
No. Author Year Country N Died
1
2
3
4
5
6
7
Ferro JM et al11
Nagaraja D et al31
Panagariya A et al20
Hamouda-M'Rad I et al 34
Cantu C C et al9
Sanchetee PC et al 32
Srinivasan13
2004
1999
1997
1995
1993
1992
1984
Multiple† 
India
India
Tunis
Mexico
India
India
77
150
64
33
67
25
138
3 (4)
26 (17)
12 (19)
12 (36)
6 (9)
3 (12)
28 (20)
^Year= year of publication, N= total number of patients in the series
*Percentages in parenthesis
†21 countries from Europe, Canada, Australia and Latin America
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CVT was also pregnancy related event.34 
Conclusion
Obstetric CVT is not uncommon. It must be consid-
ered in young women presenting with any neurologic man-
ifestation related to CNS during pregnancy (especially 3rd
trimester) and puerperium. Obstetric CVT has a different
course and carries favourable prognosis as compared to
CVT unrelated to pregnancy. There is evidence that mortal-
ity can be altered favourably by anticoagulation. The treat-
ment of obstetric CVT is similar to CVT unrelated to preg-
nancy, including conventional anticoagulation. Low dose
subcutaneous is viable/feasible and potentially efficacious
option, however, this needs to be confirmed in controlled
randomized trials.
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